BioWorld

Nov. 12, 2004

OSI Offering Garners $387M; Tarceva Waiting On Runway

With 6 million shares offered at $64.50 each, OSI Pharmaceuticals Inc. is raising $387 million while waiting with partner Genentech Inc. for word from the FDA regarding Tarceva, their drug for non-small-cell lung cancer. (BioWorld Today) Read More

Zephyr Getting Neuprex In Potential $73M XOMA Deal

Geron Raises $40M Privately To Fund Oncology Products

Inspire Pharmaceuticals Gets $37.6M In Sale Of Public Stock

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...